Treatment patterns and health care costs of mebeverine-treated IBS patients: A case-control study

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 11, 2004, Pages 803-810

  Goettsch, Wim G ^a   van den Boom, Guido ^b   Breekveldt Postma, Nancy S ^a   Smout, André J P M ^c   Herings, Ron M C ^a,d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b Novartis Pharma BV   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Co medication; Health care costs; Hospital morbidity; Incidence; Irritable bowel syndrome; Laxatives; Matched case control study; Mebeverine

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BETA LACTAM ANTIBIOTIC; BULKING AGENT; CARDIOVASCULAR AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPNOTIC AGENT; IRON; LAXATIVE; LINCOSAMIDE DERIVATIVE; MACROLIDE; MEBEVERINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEDATIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CASE CONTROL STUDY; CONSTIPATION; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; SEX DIFFERENCE; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CATHARTICS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IRRITABLE BOWEL SYNDROME; LOGISTIC MODELS; MEDICAL RECORD LINKAGE; MIDDLE AGED; NETHERLANDS; PARASYMPATHOLYTICS; PHARMACOEPIDEMIOLOGY; PHENETHYLAMINES; PREVALENCE;

EID: 8644250763     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.997     Document Type: Article

References (25)

1. Donker GA, Foets M, Spreeuwenberg P. Patients with irritable bowel syndrome: health status and use of health care services. Br J Gen Pract 1999; 49: 787-792.
2. Haubrich WS. Clinical features of the irritable bowel syndrome. Gastrointest Endosc 1980; 26: 24S-25S.
3. Kay L, Jorgensen T, Jensen KH. The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors. J Intern Med 1994; 236: 23-30.
4. Kay L, Jorgensen T, Jensen KH. [Irritable colon among 30-60-year old subjects. A cohort study of 4581 Danes]. Ugeskr Laeger 1995; 157: 3476-3480.
5. Osterberg E, Blomquist L, Krakau I, Weinryb RM, Asberg M, Hultcrantz R. A population study on irritable bowel syndrome and mental health. Scand J Gastroenterol 2000; 35: 264-268.
6. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001; 19: 643-653.
7. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 371-384.
8. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-147.
9. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107: 91S-97S.
10. van der Horst HE, Meijer JS, Muris JWM. NHG-Standard Prikkelbaar Darm Syndroom. Huisarts Wetenschap 2001; 44 : 58-65.
11. Anonymous. Farmacotherapeutisch Kompas. Amstelveen; 1999.
12. van der Horst HE. Her prikkelbaredarmsyndroom: is er een plaats voor medicamenteuze therapie. Geneesmiddelenbulletin 2001; 36: 15-21.
13. Talley NJ. Drug therapy options for patients with irritable bowel syndrome. Am J Manag Care 2001; 7: S261-S267.
14. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-1666.
15. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-468.
16. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001; 19: 655-665.
17. Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997; 92: 954-959.
18. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. Br Med J 1999; 318: 565-566.
19. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997; 314: 779-782.
20. Anonymous. Classificatie Van Ziekten, Systematisch. (3rd edition). SIG Zorginformatie: Utrecht, The Netherlands; 1999.
21. Wiedijk I, Spierings P. Technische Brochure: Opbouw en Organisatie Van Her CBV-Bestand. Stichting CBV. Leiden; 1999.
22. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-349.
23. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344: 1846-1850.
24. Su YC, Wang WM, Wang SY, et al. The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1900-1905.
25. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000; 17: 331-338.